Patient characteristics and CT scores for the study cohorts in the three transplant centres
| Centre | 1 | 2 | 3 | Total |
| n | 10 | 12 | 35 | 57 |
| Males | 5 (50%) | 8 (67%) | 21 (60%) | 34 (60%) |
| Age (years) | 28.5 (16–38) | 32.2 (16–49) | 24.4 (17–53) | 26.7 (16–53) |
| BMI (kg/m2) | 19.5 (16–26) | 20.0 (18–22) | 19.0 (15–27) | 19.0 (15–27) |
| Pancreatic insufficiency | 8 (80%) | 10 (83%) | 34 (97%) | 52 (91%) |
| Diabetes mellitus | 5 (50%) | 3 (25%) | 9 (26%) | 17 (30%) |
| Microbiology | ||||
| Pseudomonas aeruginosa | 10 (100%) | 11 (92%) | 32 (92%) | 53 (93%) |
| Burkholderia cepacia complex | 0 | 2 (17%) | 2 (6%) | 4 (7%) |
| FEV1 (% predicted) | 24 (19–34) | 26 (15–38) | 27 (13–45) | 26 (13–45) |
| FVC (% predicted) | 43 (25–70) | 42 (29–67) | 43 (24–89) | 42 (24–89) |
| Brody-II scores | ||||
| Total score | 40 (32–60) | 48 (33–59) | 34 (17–52) | 37 (17–60) |
| Bronchiectasis | 44 (29–57) | 60 (35–72) | 36 (25–60) | 41 (25–72) |
| Mucus plugging | 31 (25–47) | 16 (8–42) | 19 (0–42) | 25 (0–47) |
| Airway wall thickening | 31 (19–63) | 54 (26–69) | 35 (15–60) | 36 (15–69) |
| Opacities | 11 (6–26) | 15 (7–26) | 9 (0–22) | 11 (0–26) |
| SALD scores | ||||
| Infection/inflammation | 24 (17–30) | 23 (17–41) | 23 (9–43) | 24 (9–43) |
| Air trapping/hypoperfusion | 48 (27–61) | 36 (28–68) | 43 (24–61) | 43 (24–68) |
| Bulla/cysts | 0 (0–11) | 4.5 (0–39) | 0 (0–13) | 0 (0–39) |
| Normal/hyperperfusion | 29 (21–43) | 31 (10–46) | 31 (20–51) | 30 (10–51) |
Data are given as patient numbers (%) or as median (range).
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SALD, severe advanced lung disease.